Results 141 to 150 of about 30,272 (291)

Strong capacity of differentiated PD-L1 CAR-modified UCB-CD34+ cells and PD-L1 CAR-modified UCB-CD34+-derived NK cells in killing target cells and restoration of the anti-tumor function of PD-1-high exhausted T Cells

Stem Cell Research & Therapy
Background Using natural killer (NK) cells to treat hematopoietic and solid tumors has great promise. Despite their availability from peripheral blood and cord blood, stem cell-derived NK cells provide an “off-the-shelf” solution.
Farhoodeh Ghaedrahmati, Vajihe Akbari, Hooria Seyedhosseini-Ghaheh, Nafiseh Esmaeil   +3 more
doaj   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Safety, Efficacy and Determinants of Response of Allogeneic CD19-Specific CAR-NK Cells in CD19+ B Cell Tumors: A Phase 1/2 Trial [PDF]

There is a pressing need for allogeneic chimeric antigen receptor (CAR)-immune cell therapies that are safe, effective and affordable. We conducted a phase 1/2 trial of cord blood-derived natural killer (NK) cells expressing anti-CD19 chimeric antigen ...
Acharya, Sunil, Ammari, Mariam, Ang, Sonny, Banerjee, Pinaki, Basar, Rafet, Bassett, Roland, Cao, Kai, Champlin, Richard E, Chen, Ken, Daher, May, Dede, Merve, Dou, Jinzhuang, Flowers, Christopher R, Ganesh, Christina, Hosing, Chitra, Kaplan, Mecit, Kebriaei, Partow, Li, Ye, Lin, Paul, Liu, Enli, Macapinlac, Homer A, Marin, David, Mohanty, Vakul, Moseley, Sadie Mae, Nastoupil, Loretta J, Nieto, Yago, Popat, Uday R, Qazilbash, Muzaffar H, Rafei, Hind, Rao, Sheetal, Rezvani, Katayoun, Shanley, Mayra, Shpall, Elizabeth J, Thall, Peter F, Uprety, Nadima, Wilson, Jeffrey   +35 more
core   +1 more source

Reprogramming tumor immune microenvironment by ultrasound‐responsive nanoplatforms for enhanced cancer immunotherapy

BMEMat, EarlyView.
Ultrasound‐responsive nanoplatforms reprogram the tumor immune microenvironment by targeting tumor cells, immune cells, and non‐immune stromal cells to enhance the efficacy of cancer immunotherapy. Abstract Cancer immunotherapy represents a significant advancement in cancer treatment by enhancing the specific recognition and elimination of cancer cells.
Shilong Zhao, Rui Qu, Zan Dai, Xiqun Jiang, Xu Zhen   +4 more
wiley   +1 more source

Development of a scalable and robust upstream process for the chemically-defined production of lentiviral vectors for gene-modified cellular immunotherapies [PDF]

Ex vivo gene-modified cellular immunotherapy, including chimeric antigen receptor (CAR)-T and CAR-NK cell therapy, is a promising therapeutic modality for the treatment of various diseases and has demonstrated remarkable clinical outcomes for indications
Ripoll Fiol, Carme
core  

CAR-NK-Zellen: die nächste Innovation der Krebsimmuntherapie?

BIOspektrum
Abstract CAR-NK cells offer a promising immunotherapy approach, addressing key CAR-T cell limitations like reduced toxicity risks while retaining targeted efficacy. They combine the innate cytotoxicity of natural killer (NK) cells with the targeted action of chimeric antigen receptors (CAR).
Katharina Schindler-Wnek, Dominik Schmiedel   +1 more
openaire   +1 more source

Optimisation of a primary human CAR‐NK cell manufacturing pipeline

Clinical & Translational Immunology
AbstractObjectivesAutologous chimeric antigen receptor (CAR) T‐cell therapy of B‐cell malignancies achieves long‐term disease remission in a high fraction of patients and has triggered intense research into translating this successful approach into additional cancer types.
Pfefferle, Aline, Contet, Julian, Wong, Kahlia, Chen, Charlotte, Verhoeyen, Els, Slichter, Chloe, Schluns, Kimberly, Cursons, Joseph, Berry, Richard, Nikolic, Iva, Rautela, Jai, Huntington, Nicholas   +11 more
openaire   +3 more sources

Mimic, target, and adapt: Cell membrane‐coated nanoplatforms for precision and immune‐guided cancer treatment

BMEMat, EarlyView.
This Perspective explores the emerging landscape of cell membrane‐coated nanoparticles (CM‐NPs) as intelligent, immune‐compatible platforms for cancer therapy. Highlighting design strategies, translational challenges, and competitive positioning, it outlines how integrating biomimetic targeting with advanced analytical and manufacturing tools could ...
A. K. M. M. Alam, Xiaojun Cai, Malik Ihsan Ullah Khan, Robert Musiol, Quazi T. H. Shubhra   +4 more
wiley   +1 more source

CAR-NK Cell Therapy: A Transformative Approach to Overcoming Oncological Challenges

Biomolecules
The use of chimeric antigen receptor (CAR) in natural killer (NK) cells for cancer therapy is gaining momentum, marking a significant shift in cancer treatment.
Wangshu Li, Xiuying Wang, Xu Zhang, Aziz ur Rehman Aziz, Daqing Wang   +4 more
doaj   +1 more source

Ultrasmall Fe‐curcumin immunomodulators reinvigorate CAR‐T cells to potentiate solid tumor immunotherapy by mitigating cell exhaustion and senescence

BMEMat, EarlyView.
This work discovered a novel research that ultrasmall Fe‐curcumin immunomodulators could reinvigorate CAR‐T cells to potentiate solid tumor immunotherapy by mitigating cell exhaustion and senescence. Abstract CAR‐T cell immunotherapy has achieved exciting success in hematologic malignancies, but the therapeutic efficacy is relatively limited in solid ...
Jiazhi Duan, Yuchan Xue, Miao Zhang, Zihao Zhang, Shiyu Peng, Minghao Sui, Han Ding, Yingying Nie, Yuemin Feng, Le Wang, Tianru Zhang, Mingchuan Yu, He Xia, Hong Liu, Qiang Zhu, Songbo Zhao   +15 more
wiley   +1 more source